News | Prostate Cancer | October 27, 2016

Augmenix Announces Positive Three-year SpaceOAR Clinical Trial Results

Application of SpaceOAR hydrogel results in lower long-term rectal injury and higher patient quality of life scores

Augmenix, SpaceOAR System, prostate cancer, three-year clinical data results, ASTRO 2016

October 27, 2016 — Augmenix Inc. announced the three-year results from the SpaceOAR System Prostate Cancer US Pivotal Clinical Trial in September at the 2016 annual meeting of the American Society for Radiation Oncology (ASTRO).

The study results, presented by Daniel Hamstra, M.D., Ph.D., a radiation oncologist at Texas Oncology in Irving, Texas, demonstrated significantly lower rectal toxicity and higher patient quality of life (QOL) scores when the SpaceOAR System was applied prior to radiotherapy as compared to the trial control patients.

The leading side effects of prostate cancer radiotherapy are collectively known as “rectal toxicity” (diarrhea, rectal bleeding, urgency, pain, etc.), which results from unintended radiation injury to the rectum (the Organ At Risk, OAR). These complications can last for years, significantly impacting QOL. The SpaceOAR System was developed to push the rectum away from the high dose region during treatment, and then to be completely absorbed by the body after radiotherapy is complete.

The prospective, randomized, multi-center, patient-blinded clinical trial evaluated rectal and urinary toxicity and QOL impact on prostate radiotherapy patients treated either with SpaceOAR hydrogel, or with no hydrogel (controls). Previously published initial study results demonstrated spacer safety, and a significant 74 percent reduction in the volume of rectum receiving 70 Gy radiation at 15 months.

Following radiotherapy through three years, no SpaceOAR patients (0 percent) experienced grade 2 or worse late rectal toxicity, compared to 5.7 percent in the control patients (p=0.012). Additionally, at three years the average SpaceOAR patient bowel QOL was slightly better than before radiotherapy (+0.48 points), while the control patients QOL had significantly declined (-5.3 points, p=0.05). The percent of men with significant 10+ declines in bowel QOL at three years was 20.5 percent and 5.4 percent in the control and SpaceOAR groups (p=0.02), respectively.

Unexpectedly, the SpaceOAR patients also showed benefits in urinary complications and QOL, relative to controls. In the three years after radiotherapy, grade 1 urinary incontinence was experienced in 19.6 percent and 4.3 percent of the control and SpaceOAR patients, respectively (p=0.003). Additionally, like bowel QOL, at three years the average SpaceOAR patient urinary QOL was slightly better than before radiotherapy (+0.6 points), while the control patient QOL had declined (-3.3 points, p=0.05).

“The low level of rectum radiation dose seen in the men who received the spacer in this trial is unprecedented, and it is great to see that the spacer rectum protection is resulting in long-term patient benefits,” said Hamstra. “The idea that three years after treatment patients can be having the same bowel and urinary QOL is wonderful. Essentially patients can complete their treatment and be confident that life can return to normal.”

Using a minimally invasive procedure, the SpaceOAR System is injected as a liquid into the space between the prostate and rectum, where it expands the space and then solidifies into a soft hydrogel. The hydrogel remains stable for three months while protecting the rectum during radiotherapy, and then liquefies and is completely absorbed.

The SpaceOAR System is U.S. Food and Drug Administration (FDA)-cleared, CE marked and is also approved in Australia and Canada.

For more information: www.augmenix.com

Related Content

RayStation Replacing Existing Treatment Planning System at Leeds Cancer Centre
News | Treatment Planning | September 24, 2018
RaySearch recently strengthened its position in the U.K. market with a major order for the treatment planning system...
Turkish Hospital Begins MR-Guided Radiation Therapy With Viewray MRIdian Linac
News | Image Guided Radiation Therapy (IGRT) | September 21, 2018
ViewRay Inc. announced that Acibadem Maslak Hospital in Istanbul, Turkey has begun treating patients with ViewRay's...
Machine Learning IDs Markers to Help Predict Alzheimer's

Neurologists use structural and diffusion magnetic resonance imaging (MRI) to identify changes in brain tissue (both gray and white matter) that are characteristic of Alzheimer's disease and other forms of dementia. The MRI images are analyzed using morphometry and tractography techniques, which detect changes in the shape and dimensions of the brain and in the tissue microstructure, respectively. In this example, the images show the normal brain of an elderly patient. Image courtesy of Jiook Cha.

News | Neuro Imaging | September 20, 2018
New research has shown a combination of two different modes of magnetic resonance imaging (MRI), computer-based...
Exact Imaging Partners to Improve Prostate Cancer Detection With Artificial Intelligence
News | Prostate Cancer | September 19, 2018
Exact Imaging, makers of the ExactVu micro-ultrasound platform, has partnered with U.K.-based Cambridge Consultants to...
Amar Kishan, M.D.

Amar Kishan, M.D.

News | Prostate Cancer | September 11, 2018
UCLA researchers have discovered that a combination of high doses of...
Boston Scientific to Acquire Augmenix Inc.
News | Patient Positioning Radiation Therapy | September 07, 2018
Boston Scientific has entered into a definitive agreement to acquire Augmenix Inc., a privately-held company which has...

Image courtesy of IBA

Feature | Radiation Oncology | September 07, 2018 | By Jeff Zagoudis
According to the latest statistics from the American Cancer Society (ACS), almost 165,000 new cases of prostate cancer...
PET Imaging Agent Predicts Brain Tau Pathology, Alzheimer's Diagnosis
News | PET Imaging | September 05, 2018
Eli Lilly and Co. and Avid Radiopharmaceuticals Inc. announced a Phase 3 study of positron emission tomography (PET)...
Check-Cap Announces Interim Results of European Study of C-Scan System Version 3
News | Colonoscopy Systems | September 04, 2018
Check-Cap Ltd. announced the interim results for its post-CE approval study of the C-Scan system Version 3, an...
Brain Iron Levels May Predict Multiple Sclerosis Disabilities
News | Neuro Imaging | August 31, 2018
A new, highly accurate magnetic resonance imaging (MRI) technique can monitor iron levels in the brains of multiple...